DBV Technologies: Peanut Allergy Patch Advances to Key Stage
DBV Technologies has announced the filing of its Form 10-K with the U.S. Securities and Exchange Commission and its Universal Registration Document 2025 with the French Financial Markets Authority for the fiscal year 2025.
The biopharmaceutical company DBV Technologies has filed its regulatory compliance documents for the year 2025. The Form 10-K was submitted to the SEC in the United States, while the Universal Registration Document 2025 was sent to the AMF in France. These documents are publicly accessible on the company's website, as well as on the official platforms of the SEC and the AMF.
Focus on Allergy Treatments and Immunological Conditions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
DBV Technologies continues to specialize in the development of treatments for food allergies and immunological disorders. The company is currently focusing on the study of its proprietary technology, the VIASKIN® patch, based on epicutaneous immunotherapy (EPIT). Ongoing clinical programs include studies with the VIASKIN® peanut patch in young children (ages 1 to 3) and children (ages 4 to 7) allergic to peanuts.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
